Correlation of Osteocalcin and Fetuin-A levels with Renal Function and Other Biomarkers in CKD patients from Baghdad
Abstract
Background: This investigation aims to determine if a correlation existed between the levels of Osteocalcin, Fetuin-A, and other biochemical markers in patients with CKD compared to healthy.
Methods: One hundred eighty samples divided into 120 (CKD) patients in end-stage divided into 70 males and 50 females, and 60 healthy controls 35 males and 25 females were taken between November 2022 and March 2023 from three major hospitals in Baghdad. diagnosed using symptoms, biochemical testing, history, and clinical examination by specialized nephrologists. Urea, creatinine, calcium, albumin, and phosphate were measured by spectrophotometer (Roche Cobas C111). Furthermore, a spectrophotometer (Beckman coulter au480) was used to measure sodium and potassium levels. On the other hand, vitamin D3 level and PTH were measured by spectrophotometer (Roche Cobas E411). Moreover, Osteocalcin and Fetuin-A were done by ELISA technique.
Results: The present study found that the male patients are more than females, and the highest percentage of CKD cases were found in the age group of 50-59 years. also, indicates a strong positive correlation between the levels of Fetuin-A and GFR. while a strong negative correlation between the levels of Fetuin-A with creatinine, urea, and Osteocalcin, moreover, a strong negative correlation between the level of Osteocalcin with GFR and Fetuin-A. The study also found a strong positive correlation between the levels of Osteocalcin with urea and creatinine.
Conclusion: Decreased Fetuin-A concentrations have been linked to increased calcification in the vasculature and mortality, increased Osteocalcin levels in CKD may not confer a protective effect against bone disorders.
Full Text:
PDFReferences
Decreased G. Definition and classification of CKD. Kidney International, (2013); 319-62.
Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. Renal fibrosis: mechanisms and therapies, (2019); 3-15.
Vallianou NG, Mitesh S, Gkogkou A, Geladari E. Chronic kidney disease and cardiovascular disease: is there any relationship? Current cardiology reviews, (2019); 15(1): 55-63.
Suliman ME, García‐López E, Anderstam B, Lindholm B, Stenvinkel P. Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on fetuin‐A in chronic kidney disease. Advances in clinical chemistry, (2008); 46217-262.
Jahnen-Dechent W, Heiss A, Schäfer C, Ketteler M. Fetuin-A regulation of calcified matrix metabolism. Circulation research, (2011); 108(12): 1494-1509.
Wei J, Karsenty G. An overview of the metabolic functions of osteocalcin. Reviews in Endocrine and Metabolic Disorders, (2015); 1693-98.
Qaradakhi T, Gadanec LK, Tacey AB, Hare DL, Buxton BF, et al. The effect of recombinant undercarboxylated osteocalcin on endothelial dysfunction. Calcified tissue international, (2019); 105546-556.
Kyriakidis NC, Cobo G, Dai L, Lindholm B, Stenvinkel P. Role of uremic toxins in early vascular ageing and calcification. Toxins, (2021); 13(1): 26.
Tacey A, Qaradakhi T, Brennan-Speranza T, Hayes A, Zulli A, et al. Potential role for osteocalcin in the development of atherosclerosis and blood vessel disease. Nutrients, (2018); 10(10): 1426.
Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nature Reviews Nephrology, (2018);
(3): 151-164.
Xu S, Li YC, Chen CX. The Prevalence of Chronic Kidney Disease in Hypertensive Patients in Primary Care in Hong Kong: A Cross-Sectional Study. (2020).
Malekmakan L, Khajehdehi P, Pakfetrat M, Malekmakan A, Mahdaviazad H, et al. Prevalence of chronic kidney disease and its related risk factors in elderly of Southern Iran: A population-based study. International Scholarly Research Notices, (2013); 2013.
Otero González A, de Francisco A, Gayoso P, García F, Group ES. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrología (English Edition), (2010); 30(1): 78-86.
Kim HJ, Ryu H, Kang E, Kang M, Han M, et al. Metabolic acidosis is an independent risk factor of renal progression in Korean chronic kidney disease patients: The KNOW-CKD study results. Frontiers in Medicine, (2021); 8707588.
Nichols GA, Déruaz-Luyet A, Brodovicz KG, Kimes TM, Rosales AG, et al. Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes. BMC nephrology, (2020); 21(1): 1-10.
Hassan EA. Biochemical Study in Iraqi Patients with Chronic Renal Failure Therapy by Regular Hemodialysis. Diyalysis Journal For Pure Science, (2018); 14(4): 1-13.
Chang T-J, Zheng C-M, Wu M-Y, Chen T-T, Wu Y-C, et al. Relationship between body mass index and renal function deterioration among the Taiwanese chronic kidney disease population. Scientific reports, (2018); 8(1): 6908.
Lu JL, Kalantar-Zadeh K, Ma JZ, Quarles LD, Kovesdy CP. Association of body mass index with outcomes in patients with CKD. Journal of the American Society of Nephrology: JASN, (2014); 25(9): 2088.
Habas Sr E, Eledrisi M, Khan F, Elzouki A-NY, Khan FY. Secondary hyperparathyroidism in chronic kidney disease: pathophysiology and management. Cureus, (2021); 13(7).
Centeno PP, Herberger A, Mun H-C, Tu C, Nemeth EF, et al. Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion. Nature communications, (2019); 10(1): 4693.
Akimbekov NS, Digel I, Sherelkhan DK, Razzaque MS (2022) Vitamin D and phosphate interactions in health and disease. Phosphate Metabolism: From Physiology to Toxicity: Springer. pp. 37-46.
Chielle EO, Rigon KA, Arcari IA, Stein V, Santos GAd. Influência da hemodiálise na concentração plasmática da adenosina deaminase em pacientes com doença renal crônica. Jornal Brasileiro de Patologia e Medicina Laboratorial, (2015); 51153-157.
Kadhim HM, Al-Ghanimi HH, Al-Dedah RM. Haematological parameters and biochemical indices in patients with chronic kidney disease before haemodialysis Al-Furat Al-Awsat Governorates/Iraq; 2020. AIP Publishing.
Kolagal V, Karanam S, Dharmavarapu P, D'Souza R, Upadhya S, et al. Determination of oxidative stress markers and their importance in early diagnosis of uremia-related complications. Indian Journal of Nephrology, (2009); 19(1): 8.
Hassen HF, Al-Lami MQD, Al-Saedi AJH. Evaluation some biochemical levels in patients undergoing hemodialysis in Baghdad Governorate. Journal of Advanced Laboratory Research in Biology, (2018); 9(2): 50-57.
Kasper D, Fauci A, Hauser S, Longo D, Jameson J, et al. Harrison's principles of internal medicine, 19e. Chapter: Book Name. 2015 of publication; 1; Mcgraw-hill New York, NY, USA:.
Lang J, Katz R, Ix JH, Gutierrez OM, Peralta CA, et al. Association of serum albumin levels with kidney function decline and incident chronic kidney disease in elders. Nephrology Dialysis Transplantation, (2018); 33(6): 986-992.
Janmaat CJ, Van Diepen M, Gasparini A, Evans M, Qureshi AR, et al. Lower serum calcium is independently associated with CKD progression. Scientific reports, (2018); 8(1): 5148.
Franca Gois PH, Wolley M, Ranganathan D, Seguro AC. Vitamin D deficiency in chronic kidney disease: recent evidence and controversies. International journal of environmental research and public health, (2018); 15(8): 1773.
Fourtounas C. Phosphorus metabolism in chronic kidney disease. Hippokratia, (2011); 15(Suppl 1): 50.
Gluba-Brzózka A, Michalska-Kasiczak M, Franczyk-Skóra B, Nocuń M, Banach M, et al. Markers of increased cardiovascular risk in patients with chronic kidney disease. Lipids in health and disease, (2014); 131-13.
Nessim IG, el Wahab AA, Madani HA, Waked E, el Khalek AA, et al. Evaluation of serum osteoprotegerin and fetuin A levels in Egyptian patients with chronic kidney disease. Comparative Clinical Pathology, (2011); 20421-425.
Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney international, (2005); 67(3): 1070-1077.
Schäfer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, et al. The serum protein α 2–Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. The Journal of clinical investigation, (2003); 112(3): 357-366.
Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. The Lancet, (2003); 361(9360): 827-833.
Razzaque MS. Osteocalcin: a pivotal mediator or an innocent bystander in energy metabolism? Nephrology Dialysis Transplantation, (2011); 26(1): 42-45.
Zhang M, Ni Z, Zhou W, Qian J. Undercarboxylated osteocalcin as a biomarker of subclinical atherosclerosis in non-dialysis patients with chronic kidney disease. Journal of Biomedical Science, (2015); 221-7.
Guo X, Li Y, Zhou Y, Zhang C, Liang S, et al. Osteocalcin association with vascular function in chronic kidney disease. The Journal of Clinical Hypertension, (2022); 24(7): 928-936.
Refbacks
- There are currently no refbacks.